Much of AI in Pharma focuses on drug discovery. Yet bringing innovation to patients takes years of clinical trials and regulatory work. Today we're launching KIRHA Life Sciences to shorten the time between a scientific discovery and the day it helps a patient. We can accelerate the work surrounding clinical trials: designing protocols, preparing CDISC datasets for regulatory submissions, and monitoring drug safety through pharmacovigilance (PV) and real-world evidence (RWE). We've spent 18 months building context infrastructure for AI agents, serving 500,000+ requests through our network of 800+ provider's tools. That taught us what agents need in regulated workflows: verifiable search, curated data, and privacy from inference to context. KIRHA has always been a context company. Now we're also taking on the coding behind some of the most regulated work in the industry, with OpenSAS, our open-source runtime compatible with SAS 9.4. It's already attracting contributions from the scientific community, including Yilong Zhang and members of R Consortium Pilot 7, who have been benchmarking it on agentic SDTM and ADaM pipelines. On Nov 24, we'll show how we're speeding up @CDISC programming with eXYSTAT at DMB Congress in Paris. DM me if you'd like to join.